Physician profile
Daniel Ying Wang
NPI 1679834329
$11,345.64
in general payments reported to CMS, 2019-2025
23 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $2,375 · 2021: $69.95 · 2022: $863 · 2023: $2,350 · 2024: $3,424 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,636 · Food and Beverage: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,636.00 |
| Food and Beverage | $3,155.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $4,736.00 | 2020-2024 | Libtayo |
| Stryker Corporation | $3,309.54 | 2022-2024 | Mako, Gamma, Axsos |
| Springworks Therapeutics, INC. | $2,000.00 | 2025 | Ogsiveo |
| Depuy Synthes Sales INC. | $435.60 | 2019-2020 | |
| Ermi LLC | $124.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $107.07 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $94.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $93.39 | 2022 | |
| Heraeus Medical, LLC. | $86.26 | 2019 | |
| Tempus Ai, INC | $74.01 | 2024 | |
| Aveo Pharmaceuticals, INC. | $50.44 | 2022 | |
| Amgen INC. | $44.33 | 2022 | |
| Inspire Medical Systems, INC. | $40.83 | 2023 | Inspire |
| Genzyme Corporation | $24.92 | 2022 | |
| Incyte Corporation | $24.04 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $23.18 | 2021 | |
| Bioventus LLC | $21.80 | 2023 | Durolane |
| Janssen Biotech, INC. | $20.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.20 | 2025 | Camzyos |
| Helsinn Therapeutics (U.S.), INC. | $16.99 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.